Detection of aberrant androgen receptor transcripts in circulating tumour cells as a predictor of resistance to AR- directed treatment in patients with castration-resistant prostate cancer.
- Conditions
- 10027656castration-resistent prostate cancerprogression during hormonal treatment
- Registration Number
- NL-OMON42793
- Lead Sponsor
- niversiteit Antwerpen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 15
Inclusion Criteria
1. Willing and able to provide written informed consent
2. Male and age >= 18 years
3. Histologically or cytologically confirmed adenocarcinoma of the prostate
4. Patients eligible to receive enzalutamide or abiraterone acetate as judged by the treating physician
5. Patients with or without prior chemotherapy regimens
Exclusion Criteria
1. Serious or uncontrolled co-existent non-malignant disease, including active and uncontrolled infection.
2. Not willing to comply with the procedural requirements (extra blood draw) of this protocol.
3. Any criteria which renders patients ineligible for new AR-directed therapy (i.e. abiraterone acetate, enzalutamide).
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The determination of the clinical relevance for the presence or absence of<br /><br>androgen receptor splice variants in circulating tumour cells from patients<br /><br>with CRPC (with or without previous taxane chemotherapy) is the primary<br /><br>endpoint of this study.</p><br>
- Secondary Outcome Measures
Name Time Method <p>NA</p><br>